You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letters
Routine probiotics in preterm infants?
  1. Florian Guthmann,
  2. Christoph Bührer
  1. Department of Neonatology, Charité Universitätsmedizin Berlin, Berlin, Germany
  1. Correspondence to Christoph Bührer, Department of Neonatology, Charité Universitätsmedizin Berlin, Berlin D-13344, Germany; christoph.buehrer{at}charite.de

https://doi.org/10.1136/adc.2010.208710

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A commissioned commentary by Millar et al1 and a recent statement from the American Academy of Pediatrics2 complain about the lack of defined probiotic products that are licensed by regulatory authorities. A commercially available combination of Lactobacillus acidophilus and Bifidusbacterium infantis (Infloran), given to a total of 1725 preterm infants within the framework of two open-label and two randomised controlled trials without side effects,3 has been shown to reduce necrotising enterocolitis (NEC) and …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.